ICER’s RWE Study of Hereditary Angioedema Treatments Provides New Insight

The Institute for Clinical and Economic Review (ICER) recently published results from a real world evidence study (RWE) assessing the efficacy and cost-effectiveness of three drugs used in cases of hereditary angioedema (HAE). The study provided a unique perspective and ICER noted an updated pricing recommendation.

“[R]esults of the re-analysis of three HAE treatments aren’t necessarily expected to be typical for RWE-based updates undertaken in the future by the Institute for Clinical and Economic Review.” Read more here.

(Source: Cathy Kelly, Pink Sheet, 8/27/21)